Risk for Later Invasive Breast Cancer Up for Women With DCIS
THURSDAY, May 28, 2020 -- Women with screening-detected ductal carcinoma in situ (DCIS) have increased long-term risks for invasive breast cancer and breast cancer death, according to a study published online May 27 in The BMJ. Gurdeep S. Mannu,...
ConclusionsIn summary, high expression of C7 may promote breast cancer development and might be insensitive to TE-based chemotherapy. Our present study laid a foundation to help clinicians improve the identification of patients for TE-based chemotherapy by C7 in the era of precision medicine.
CONCLUSION: Non-surgical management of pure LN is safe, and the likelihood of requiring subsequent surgical excision or repeat CNB during follow-up is low. These data provide reassurance that routine excision of pure LN in the setting of radiologic-pathologic concordance is not required.PMID:34554341 | DOI:10.1245/s10434-021-10827-z
Mastectomy and breast conserving surgery (BCS) followed by whole breast radiotherapy (WBRT) are the standard therapeutic options for patients with ductal carcinoma in situ (DCIS), although no randomized clinical trial has compared these two strategies. Adjuvant WBRT, in which 50 Gy are delivered in 25 fractions over 5 weeks after BCS, significantly increases the local control rate with low toxicity incidence [1,2]. After the European Organization for Research and Treatment of Cancer (EORTC) trial results, a radiotherapy boost is standard practice in patients with invasive breast cancer after BCS.
1. DCISM patients had a good survival, even those with DCIS component ≥5 cm.2. Patients aged
CONCLUSION: In DCIS patients, the rate of second breast cancers was 7.5%. Breast conservation, involved margins after lumpectomy and shortened hormonal therapy were associated with second cancers. Patients with involved margins after lumpectomy have the highest cancer detection rate and minimal unnecessary biopsies and follow-ups. Hence, ipsilateral breast ultrasound surveillance could be personalized for this high-risk group with mammographically dense breasts.PMID:34544658 | DOI:10.1016/j.clbc.2021.08.006
Conclusion: This study established a COAGULATION-related gene signature and showed its prognostic value in IDC through a comprehensive bioinformatics analysis, which may provide a potential new prognostic mean for patients with IDC.
CONCLUSION: FC frequently exhibits low heterogeneity, scattered microcapsules with posterior enhancement, "pit-like" or "grid-like" changes, posterior enhancement, rare hyperechoic halo, calcification, and lack of blood supply. Certain focal FC are irregularly shaped with unclear edges, with malignant signs such as crab feet and burr, hyperechoic halo, and calcification, which ultrasound BI-RADS classification may easily misdiagnose as malignant. Local magnification function should be considered, and the internal structure should be carefully observed to prevent misdiagnosis.PMID:34535389 | DOI:10.1016/j.clbc.2021.08.004
DiscussionICG administration timing during the angiography phase compared with the EPR phase improved TBR and diagnostic accuracy. Future work will focus on image pattern analysis and adaptation of the camera system to targeting fluorophores specific to breast cancer.
Pract Radiat Oncol. 2021 Aug 30:S1879-8500(21)00225-3. doi: 10.1016/j.prro.2021.08.009. Online ahead of print.ABSTRACTPURPOSE/OBJECTIVE(S): Randomized data support accelerated partial breast irradiation (APBI) for early-stage breast cancer with variable techniques and cosmesis outcomes. We have treated patients with 5-fraction prone external beam APBI for over a decade and herein report acute and late outcomes.MATERIALS/METHODS: Patients receiving APBI 600cGy x 5 between 2010-2019 were included. APBI was primarily delivered prone, with opposed tangents targeting the tumor bed expanded by 1.5cm, (cropped 6mm from skin). Ips...
ConclusionsHigh-risk screening might facilitate downstaging of detected breast tumor among BRCA1/2 carrier population.